Hormonal contraception
PreclinicalSmall molecule
Hormonal contraception is one of 22 small molecule programs targeting Sexual Dysfunction. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Sexual Dysfunction
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Cymbalta
Jazz PharmaceuticalsApproved
Viibryd
AbbVieApproved
Estrace
Novo NordiskApproved
Buspar
Bristol-Myers SquibbApproved
Viagra
VViatris Specialty LLC
Approved
Zoloft
VViatris Specialty LLC
Approved
Tricor
JJagotec
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Abilify
OtsukaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hormonal contraception. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details